Matches in SemOpenAlex for { <https://semopenalex.org/work/W2415752015> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2415752015 endingPage "75" @default.
- W2415752015 startingPage "459" @default.
- W2415752015 abstract "A review of the relevant literature strongly suggests that several medical and laser treatments presently used in glaucoma therapy, and other potential treatments under investigation, reduce IOP, at least, in part, by stimulating endogenous PG synthesis. There are four lines of evidence leading to this conclusion. (1) PGs are potent ocular hypotensive agents. (2) Adrenergic and cholinergic agonists stimulate PG synthesis by ocular tissues in vitro. (3) Epinephrine and ALT cause elevation of PG levels in the aqueous humor in vivo. (4) PG synthesis inhibitors such as indomethacin or flurbiprofen block, or partially inhibit, the reduction of IOP produced by epinephrine, para-aminoclonidine, forskolin, vanadate, verapamil, arachidonic acid, and ALT in rabbits, cats, monkeys, and/or humans. This last finding has great clinical importance with regard to the efficacy of such treatment modalities as epinephrine and ALT, since it indicates that these modalities may be less effective in reducing IOP in glaucoma patients who are taking systemic PG synthesis inhibitors - such as aspirin or indomethacin - for arthritis, cerebrovascular disease, arteriosclerotic coronary vascular disease, headache, or the common cold. Other surgical procedures for glaucoma such as cyclocryotherapy or other cyclodestructive procedures may also reduce IOP in part by stimulating local PG synthesis. Since PGs are produced in various ocular tissues and some of these PGs are highly potent ocular hypotensive agents, their potential role in mediating the reduction of IOP produced by medical or surgical modalities of glaucoma therapy must always be considered. Furthermore, these considerations support the concept that topical application of an appropriately selected PG, or its derivative, may provide a more direct means of lowering IOP than some of the currently used procedures or therapeutic agents." @default.
- W2415752015 created "2016-06-24" @default.
- W2415752015 creator A5039302002 @default.
- W2415752015 creator A5072355184 @default.
- W2415752015 date "1989-01-01" @default.
- W2415752015 modified "2023-09-23" @default.
- W2415752015 title "The role of endogenous prostaglandins in clinically-used and investigational glaucoma therapy." @default.
- W2415752015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2508130" @default.
- W2415752015 hasPublicationYear "1989" @default.
- W2415752015 type Work @default.
- W2415752015 sameAs 2415752015 @default.
- W2415752015 citedByCount "17" @default.
- W2415752015 countsByYear W24157520152012 @default.
- W2415752015 countsByYear W24157520152018 @default.
- W2415752015 crossrefType "journal-article" @default.
- W2415752015 hasAuthorship W2415752015A5039302002 @default.
- W2415752015 hasAuthorship W2415752015A5072355184 @default.
- W2415752015 hasConcept C118487528 @default.
- W2415752015 hasConcept C126322002 @default.
- W2415752015 hasConcept C150903083 @default.
- W2415752015 hasConcept C207001950 @default.
- W2415752015 hasConcept C2775859304 @default.
- W2415752015 hasConcept C2776521421 @default.
- W2415752015 hasConcept C2776740260 @default.
- W2415752015 hasConcept C2778527774 @default.
- W2415752015 hasConcept C2781092963 @default.
- W2415752015 hasConcept C71924100 @default.
- W2415752015 hasConcept C86803240 @default.
- W2415752015 hasConcept C98274493 @default.
- W2415752015 hasConceptScore W2415752015C118487528 @default.
- W2415752015 hasConceptScore W2415752015C126322002 @default.
- W2415752015 hasConceptScore W2415752015C150903083 @default.
- W2415752015 hasConceptScore W2415752015C207001950 @default.
- W2415752015 hasConceptScore W2415752015C2775859304 @default.
- W2415752015 hasConceptScore W2415752015C2776521421 @default.
- W2415752015 hasConceptScore W2415752015C2776740260 @default.
- W2415752015 hasConceptScore W2415752015C2778527774 @default.
- W2415752015 hasConceptScore W2415752015C2781092963 @default.
- W2415752015 hasConceptScore W2415752015C71924100 @default.
- W2415752015 hasConceptScore W2415752015C86803240 @default.
- W2415752015 hasConceptScore W2415752015C98274493 @default.
- W2415752015 hasLocation W24157520151 @default.
- W2415752015 hasOpenAccess W2415752015 @default.
- W2415752015 hasPrimaryLocation W24157520151 @default.
- W2415752015 hasRelatedWork W113178316 @default.
- W2415752015 hasRelatedWork W1983398617 @default.
- W2415752015 hasRelatedWork W2034279723 @default.
- W2415752015 hasRelatedWork W2055953789 @default.
- W2415752015 hasRelatedWork W2080008723 @default.
- W2415752015 hasRelatedWork W2148250276 @default.
- W2415752015 hasRelatedWork W2159413173 @default.
- W2415752015 hasRelatedWork W2314290913 @default.
- W2415752015 hasRelatedWork W2403724064 @default.
- W2415752015 hasRelatedWork W57132350 @default.
- W2415752015 hasVolume "312" @default.
- W2415752015 isParatext "false" @default.
- W2415752015 isRetracted "false" @default.
- W2415752015 magId "2415752015" @default.
- W2415752015 workType "article" @default.